<p>Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - 獲取免費報告) 被四家研究公司給予&#34;買入&#34;評級，Marketbeat 報告稱。四位股票研究分析師對該股票給出了買入建議。過去一年發佈關於該股票報告的經紀公司中，平均一年目標價格為 8.25 美元。</p>
<p>獲取 <strong>Amneal Pharmaceuticals</strong> 警報：</p>
<ul>
<li>6 個購買 Teva Pharmaceuticals 股票的理由</li>
</ul>
<p>幾位分析師最近對 AMRX 股票發表了評論。Truist Financial 重申了&#34;買入&#34;評級，並在 5 月 6 日星期一的報告中發佈了 9.00 美元的價格目標（從 7.00 美元上調）。高盛集團將 Amneal Pharmaceuticals 的價格目標從 6.25 美元上調至 8.00 美元，並給予該公司&#34;買入&#34;評級。StockNews.com 在 3 月 4 日星期一的報告中，將 Amneal Pharmaceuticals 的評級從&#34;強烈買入&#34;調降為&#34;買入&#34;。最後，Piper Sandler 將 Amneal Pharmaceuticals 的價格目標從 6.00 美元上調至 8.00 美元，並給予該公司&#34;超配&#34;評級。</p>
<p><strong>查看我們對 AMRX 的最新分析</strong></p>
<h2>對 Amneal Pharmaceuticals 的對沖基金意見</h2>
<p>一些大型投資者最近增加或減少了他們在該股票中的持股。Vanguard Group Inc. 在第一季度將其在 Amneal Pharmaceuticals 的持股比例提高了 0.6%。Vanguard Group Inc. 現在擁有公司股票的 13,728,233 股，價值 831,930,000 美元，在此期間增加了 85,846 股。Rubric Capital Management LP 在第四季度將其在 Amneal Pharmaceuticals 的持股比例增加了 98.8%。Rubric Capital Management LP 現在擁有公司股票的 8,000,000 股，價值 485,600,000 美元，在上一季度增加了 3,975,500 股。查爾斯史瓦布投資管理公司在第四季度將其在 Amneal Pharmaceuticals 的持股比例增加了 2.1%。查爾斯史瓦布投資管理公司現在擁有公司股票的 1,329,508 股，價值 80,700,000 美元，在上一季度增加了 26,875 股。德克薩斯州教師退休系統在第四季度將其在 Amneal Pharmaceuticals 的持股比例增加了 3.4%。德克薩斯州教師退休系統現在擁有公司股票的 744,752 股，價值 45,210,000 美元，在上一季度增加了 24,651 股。最後，Phocas Financial Corp. 在第四季度購入了 Amneal Pharmaceuticals 的新股份，價值 4,339,000 美元。目前有 31.82% 的股份由機構投資者和對沖基金持有。</p>
<h2>Amneal Pharmaceuticals 股價上漲 0.4%</h2>
<p>NASDAQ: AMRX 在週五開盤價為 6.75 美元。該公司的市值為 20.8 億美元，市盈率為-12.05，β係數為 1.19。Amneal Pharmaceuticals 過去一年的最低價為 2.29 美元，最高價為 7.25 美元。該公司的流動比率為 1.65，速動比率為 0.97，負債權益比為 121.31。公司的 50 天移動平均價為 6.42 美元，200 天移動平均價為 5.88 美元。</p>
<p>Amneal Pharmaceuticals (NASDAQ: AMRX - 獲取免費報告) 上次發佈其財報是在 5 月 3 日星期五。該公司報告季度每股盈利為 0.12 美元，超過了 0.08 美元的共識預期 0.04 美元。該季度公司的營收為 6.5919 億美元，超過了 6.2308 億美元的共識預期。Amneal Pharmaceuticals 的淨利潤率為-6.76%，股東權益回報率為 234.06%。分析師預計，Amneal Pharmaceuticals 當年將實現每股盈利 0.51 美元。</p>
<h2>關於 Amneal Pharmaceuticals（獲取免費報告）</h2>
<p>Amneal Pharmaceuticals, Inc.及其子公司在全球範圍內開發、製造、銷售和分銷仿製藥、注射劑、生物類似藥和特殊品牌藥品。該公司通過三個部門運營：仿製藥、特殊品牌和 AvKARE。仿製藥部門提供即時和延長釋放口服固體、粉劑、液體、無菌注射劑、鼻噴劑、吸入和呼吸、生物類似藥、眼科、膜、透皮貼片和局部產品。</p>
<h2>精選文章</h2>
<ul>
<li>五支我們比 Amneal Pharmaceuticals 更喜歡的股票</li>
<li>3 家可提升您投資組合的家居裝修股</li>
<li>達登股票在第四季度盈利超預期後上漲，對 2025 財年展望謹慎</li>
<li>10 家最佳航空公司股票</li>
<li>Celsius 股票：為什麼派傑·桑德勒預測將大漲 50%</li>
<li>什麼是日經 225 指數？</li>
<li>安永的股票收益揭示了一項基於人工智能的增長策略</li>
</ul>
<p><em>此即時新聞警報由敍事科技和來自 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 在 Nvidia 1.10 美元時發出買入建議的人士現在説買這個...（來自牛津俱樂部）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjA5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjA5"/></p>
<h2>現在是否值得投資 1000 美元購買 Amneal Pharmaceuticals？</h2>
<p>在考慮購買 Amneal Pharmaceuticals 之前，您會想聽聽這個。</p>
<p>MarketBeat 持續追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票... 而 Amneal Pharmaceuticals 不在名單上。</p>
<p>雖然 Amneal Pharmaceuticals 目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

AMRX

<p>Amneal Pharmaceuticals（納斯達克股票代碼：AMRX）已獲得四家研究公司的 “買入” 評級。該股票的 1 年目標價為 8.25 美元，並且獲得了分析師的積極評價。機構投資者和對沖基金也對該股票表現出興趣。Amneal Pharmaceuticals 報告了季度超出預期的盈利業績</p>

<p>Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has been given an average rating of &#34;Buy&#34; by the four research firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.25.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - 獲取免費報告) 被四家研究公司給予&#34;買入&#34;評級，Marketbeat 報告稱。四位股票研究分析師對該股票給出了買入建議。過去一年發佈關於該股票報告的經紀公司中，平均一年目標價格為 8.25 美元。</p>
</div><p>Get <strong>Amneal Pharmaceuticals</strong> alerts:</p>
<ul>
<li>6 reasons to buy Teva Pharmaceuticals stock sooner than later</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>Amneal Pharmaceuticals</strong> 警報：</p>
<ul>
<li>6 個購買 Teva Pharmaceuticals 股票的理由</li>
</ul>
</div><p>Several analysts have recently commented on AMRX shares. Truist Financial reaffirmed a &#34;buy&#34; rating and issued a $9.00 price objective (up from $7.00) on shares of Amneal Pharmaceuticals in a report on Monday, May 6th. The Goldman Sachs Group upped their price objective on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a &#34;buy&#34; rating in a report on Monday, May 6th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Monday, March 4th. Finally, Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, March 21st.</p>
<div class="lb-trans"><p>幾位分析師最近對 AMRX 股票發表了評論。Truist Financial 重申了&#34;買入&#34;評級，並在 5 月 6 日星期一的報告中發佈了 9.00 美元的價格目標（從 7.00 美元上調）。高盛集團將 Amneal Pharmaceuticals 的價格目標從 6.25 美元上調至 8.00 美元，並給予該公司&#34;買入&#34;評級。StockNews.com 在 3 月 4 日星期一的報告中，將 Amneal Pharmaceuticals 的評級從&#34;強烈買入&#34;調降為&#34;買入&#34;。最後，Piper Sandler 將 Amneal Pharmaceuticals 的價格目標從 6.00 美元上調至 8.00 美元，並給予該公司&#34;超配&#34;評級。</p>
</div><p><strong>Check Out Our Latest Analysis on AMRX</strong></p>
<div class="lb-trans"><p><strong>查看我們對 AMRX 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On Amneal Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Amneal Pharmaceuticals 的對沖基金意見</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Amneal Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company's stock worth $83,193,000 after acquiring an additional 85,846 shares during the period. Rubric Capital Management LP grew its holdings in shares of Amneal Pharmaceuticals by 98.8% during the fourth quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company's stock worth $48,560,000 after buying an additional 3,975,500 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Amneal Pharmaceuticals by 2.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,329,508 shares of the company's stock worth $8,070,000 after buying an additional 26,875 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Amneal Pharmaceuticals by 3.4% during the fourth quarter. Teacher Retirement System of Texas now owns 744,752 shares of the company's stock worth $4,521,000 after buying an additional 24,651 shares in the last quarter. Finally, Phocas Financial Corp. purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth $4,339,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投資者最近增加或減少了他們在該股票中的持股。Vanguard Group Inc. 在第一季度將其在 Amneal Pharmaceuticals 的持股比例提高了 0.6%。Vanguard Group Inc. 現在擁有公司股票的 13,728,233 股，價值 831,930,000 美元，在此期間增加了 85,846 股。Rubric Capital Management LP 在第四季度將其在 Amneal Pharmaceuticals 的持股比例增加了 98.8%。Rubric Capital Management LP 現在擁有公司股票的 8,000,000 股，價值 485,600,000 美元，在上一季度增加了 3,975,500 股。查爾斯史瓦布投資管理公司在第四季度將其在 Amneal Pharmaceuticals 的持股比例增加了 2.1%。查爾斯史瓦布投資管理公司現在擁有公司股票的 1,329,508 股，價值 80,700,000 美元，在上一季度增加了 26,875 股。德克薩斯州教師退休系統在第四季度將其在 Amneal Pharmaceuticals 的持股比例增加了 3.4%。德克薩斯州教師退休系統現在擁有公司股票的 744,752 股，價值 45,210,000 美元，在上一季度增加了 24,651 股。最後，Phocas Financial Corp. 在第四季度購入了 Amneal Pharmaceuticals 的新股份，價值 4,339,000 美元。目前有 31.82% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>Amneal Pharmaceuticals Stock Up 0.4 %</h2>
<div class="lb-trans"><h2>Amneal Pharmaceuticals 股價上漲 0.4%</h2>
</div><p>NASDAQ:AMRX opened at $6.75 on Friday. The company has a market cap of $2.08 billion, a PE ratio of -12.05 and a beta of 1.19. Amneal Pharmaceuticals has a twelve month low of $2.29 and a twelve month high of $7.25. The company has a current ratio of 1.65, a quick ratio of 0.97 and a debt-to-equity ratio of 121.31. The company's 50 day moving average is $6.42 and its two-hundred day moving average is $5.88.</p>
<div class="lb-trans"><p>NASDAQ: AMRX 在週五開盤價為 6.75 美元。該公司的市值為 20.8 億美元，市盈率為-12.05，β係數為 1.19。Amneal Pharmaceuticals 過去一年的最低價為 2.29 美元，最高價為 7.25 美元。該公司的流動比率為 1.65，速動比率為 0.97，負債權益比為 121.31。公司的 50 天移動平均價為 6.42 美元，200 天移動平均價為 5.88 美元。</p>
</div><p>Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Friday, May 3rd. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. The company had revenue of $659.19 million for the quarter, compared to the consensus estimate of $623.08 million. Amneal Pharmaceuticals had a negative net margin of 6.76% and a positive return on equity of 234.06%. Analysts anticipate that Amneal Pharmaceuticals will post 0.51 EPS for the current year.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals (NASDAQ: AMRX - 獲取免費報告) 上次發佈其財報是在 5 月 3 日星期五。該公司報告季度每股盈利為 0.12 美元，超過了 0.08 美元的共識預期 0.04 美元。該季度公司的營收為 6.5919 億美元，超過了 6.2308 億美元的共識預期。Amneal Pharmaceuticals 的淨利潤率為-6.76%，股東權益回報率為 234.06%。分析師預計，Amneal Pharmaceuticals 當年將實現每股盈利 0.51 美元。</p>
</div><h2>About Amneal Pharmaceuticals (Get Free Report</h2>
<div class="lb-trans"><h2>關於 Amneal Pharmaceuticals（獲取免費報告）</h2>
</div><p>Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals, Inc.及其子公司在全球範圍內開發、製造、銷售和分銷仿製藥、注射劑、生物類似藥和特殊品牌藥品。該公司通過三個部門運營：仿製藥、特殊品牌和 AvKARE。仿製藥部門提供即時和延長釋放口服固體、粉劑、液體、無菌注射劑、鼻噴劑、吸入和呼吸、生物類似藥、眼科、膜、透皮貼片和局部產品。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Amneal Pharmaceuticals</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook</li>
<li>10 Best Airline Stocks to Buy</li>
<li>Celsius Stock: Why Piper Sandler Forecasts a 50% Surge</li>
<li>What is the Nikkei 225 index?</li>
<li>Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>五支我們比 Amneal Pharmaceuticals 更喜歡的股票</li>
<li>3 家可提升您投資組合的家居裝修股</li>
<li>達登股票在第四季度盈利超預期後上漲，對 2025 財年展望謹慎</li>
<li>10 家最佳航空公司股票</li>
<li>Celsius 股票：為什麼派傑·桑德勒預測將大漲 50%</li>
<li>什麼是日經 225 指數？</li>
<li>安永的股票收益揭示了一項基於人工智能的增長策略</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科技和來自 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Man Who Called Nvidia at $1.10 Says Buy This Now... (From The Oxford Club)(Ad)</p>
<div class="lb-trans"><p>→ 在 Nvidia 1.10 美元時發出買入建議的人士現在説買這個...（來自牛津俱樂部）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjA5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8209&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Amneal Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1000 美元購買 Amneal Pharmaceuticals？</h2>
</div><p>Before you consider Amneal Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Amneal Pharmaceuticals 之前，您會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 持續追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票... 而 Amneal Pharmaceuticals 不在名單上。</p>
</div><p>While Amneal Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Amneal Pharmaceuticals 目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

Amneal Pharmaceuticals, Inc.（納斯達克股票代碼：AMRX）被分析師一致評為 “買入”